Marstacimab‑Hncq 150 mg/mL Suppliers & Bulk Manufacturers

Available Forms: injection (prefilled syringe)

Available Strengths: 150 mg/mL

Reference Brands: Hympavzi (USA)

Category: Blood Disorder

Marstacimab-hncq is a human monoclonal IgG1 antibody that antagonizes the tissue factor pathway inhibitor (TFPI), thereby promoting thrombin generation and improving clot formation in patients with haemophilia A or B without inhibitors. It is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and adolescents (≥ 12 years) with haemophilia A without factor VIII inhibitors or haemophilia B without factor IX inhibitors.

Product Description:

Marstacimab takes the opposite approach to replacing a missing clotting factor: instead of adding what is absent, it removes a brake. Tissue factor pathway inhibitor is a natural regulator that damps down the initiation of coagulation. In a patient who already cannot clot properly, that regulator is doing more harm than good. Blocking it restores enough thrombin generation to produce a functional clot, and because the mechanism bypasses factors VIII and IX entirely, it works in haemophilia A and B alike.

It is used for routine prophylaxis in adults and adolescents aged twelve and over with severe haemophilia A without factor VIII inhibitors, or haemophilia B without factor IX inhibitors, given as a weekly subcutaneous injection after a loading dose. The practical gain is the same as with other subcutaneous prophylaxis: no venous access, no infusions, treatment that a patient can manage at home. Injection site reactions and headache are common; thrombotic events are the theoretical class risk and require monitoring.

Sourcing notes. Originator biologic, on patent, recently approved and not yet registered in every market — confirm per destination. Recombinant, not plasma-derived. Supplied in prefilled pens and syringes. Cold chain at 2–8 degrees, with a defined period permitted at room temperature before use.